Full text is available at the source.
Abstract
Subcutaneous semaglutide at a target dose of 2.4 mg weekly reduced major adverse cardiovascular events by 20% in adults with cardiovascular disease.
- The study involved adults with a body mass index of 27 kg/m² or higher and pre-existing cardiovascular disease.
- Major adverse cardiovascular events (MACE) were significantly lower in the group receiving semaglutide compared to placebo.
- This analysis aimed to explore potential mediators of the observed cardiovascular benefit.
Simplified
GLP-1 Therapies